Adenosine inhibition of lipopolysaccharide-induced interleukin-6 secretion by the osteoblastic cell line MG-63

Calcified Tissue International

Volumn 81, Issue 4, 2007, Pages 316-326

  Russell, Joseph M ^a,b   Stephenson, Graham S ^a   Yellowley, Clare E ^a   Benton, Hilary P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenosine; Inflammation; Interleukin 6; Osteoblast; Purine receptor

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY;

ADENOSINE; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; OSTEOBLASTS; OSTEOSARCOMA; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; TIME FACTORS;

EID: 34848824403     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-007-9060-y     Document Type: Article

References (78)

1. Drury AN, Szent-Györgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68:213-237
2. Fredholm BB, Chen J-F, Masino SA, Vaugeois J-M (2005) Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 45:385-412
3. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K-N, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552
4. Linden J (2005) Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67:1385-1387
5. Schulte G, Fredholm BB (2003) Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15:813
6. Burnstock G (2002) Potential therapeutic targets in the rapidly expanding field of purinergic signalling. Clin Med J R Coll Physicians 2:45-53
7. 2a agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 14:797-806
8. Kowaluk EA (1998) Adenosine modulation: a novel approach to analgesia and inflammation. Expert Opin Investig Drugs 7:535-543
9. Hayashida M, Fukuda K-i, Fukunaga A (2005) Clinical application of adenosine and ATP for pain control. J Anesthesia 19:225
10. Londos C, Cooper DMF, Wolff J (1980) Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 77:2551-2554
11. Hasko G, Deitch EA, Szabo C, Nemeth ZH, Vizi ES (2002) Adenosine: a potential mediator of immunosuppression in multiple organ failure. Curr Opin Pharmacol 2:440
12. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492
13. Shimegi S (1996) ATP and adenosine act as a mitogen for osteoblast-like cells (MC3T3-E1). Calcif Tissue Int 58:109-113
14. Burnstock G (1990) Overview. Purinergic mechanisms. Ann N Y Acad Sci 603:1b-17
15. Olah M, Stiles G (1995) Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581-606
16. Pintor J, Miras-Portugal M-T, Fredholm BB (2000) Research on purines and their receptors comes of age. Trends Pharmacol Sci 21:453-456
17. 3H]NECA in rat striatal membranes. Mol Pharmacol 29:331-346
18. Dixon A, Gubitz A, Sirinathsinghji D, Richardson P, Freeman T (1996) Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118:1461-1468
19. Kadowaki M, Takeda M, Tokita K, Hanaoka K, Tomoi M (2000) Molecular identification and pharmacological characterization of adenosine receptors in the guinea-pig colon. Br J Pharmacol 129:871-876
20. 2 release. Arthritis Rheum 42:258-267
21. Linden J (1994) Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 15:298-306
22. 2 receptors and activity is potentiated by an adenosine deaminase inhibitor and a phosphodiesterase inhibitor. Osteoarthritis Cartilage 10:34-43
23. Tesch AM, MacDonald MH, Kollias-Baker C, Benton HP (2002) Effects of an adenosine kinase inhibitor and an adenosine deaminase inhibitor on accumulation of extracellular adenosine by equine articular chondrocytes. Am J Vet Res 63:1512-1519
24. Tesch AM, MacDonald MH, Kollias-Baker C, Benton HP (2004) Endogenously produced adenosine regulates articular cartilage matrix homeostasis: enzymatic depletion of adenosine stimulates matrix degradation. Osteoarthritis Cartilage 12:349
25. 2b receptor stimulation in U373 MG cells depends on p38 mitogen activated kinase and protein kinase C. Neurochem Int 46:510-512
26. 2b Receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J Neurochem 66:1426-1431
27. 2a adenosine receptor from guinea pig brain. Neurochem Res 19:613-621
28. 2 receptor. Mol Brain Res 15:62-66
29. 2b adenosine receptors: radioligand binding, Western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol 56:705-713
30. Genetos D, Geist D, Liu D, Donahue H, Duncan R (2005) Fluid shear-induced ATP secretion mediates prostaglandin release in MC3T3-E1 osteoblasts. J Bone Miner Res 20:41-49
31. Li J, Liu D, Ke HZ, Duncan RL, Turner CH (2005) The P2X7 nucleotide receptor mediates skeletal mechanotransduction. J Biol Chem 280:42952-42959
32. You J, Jacobs CR, Steinberg TH, Donahue HJ (2002) P2Y purinoceptors are responsible for oscillatory fluid flow-induced intracellular calcium mobilization in osteoblastic cells. J Biol Chem 277:48724-48729
33. Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA, De Somer P (1977) Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother 12:11-15
34. Angeli A, Dovio A, Sartori ML, Masera RG, Ceoloni B, Prolo P, Racca S, Chiappelli F (2002) Interactions between glucocorticoids and cytokines in the bone microenvironment. Ann N Y Acad Sci 966:97-107
35. Dovio A, Masera RG, Sartori ML, Racca S, Angeli A (2001) Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells. Calcif Tissue Int 69:299-304
36. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N (1995) Modulation of osteoclast differentiation by local factors. Bone 17:87S-91S
37. Wong P, Quinn J, Sims N, Nieuwenhuijze A, Campbell I, Wicks I (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54:158-168
38. Ohsaki Y, Takahashi S, Scarcez T, Demulder A, Nishihara T, Williams R, Roodman GD (1992) Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 131:2229-2234
39. Reddy S, Takahashi S, Dallas M, Williams R, Neckers L, Roodman GD (1994) Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res 9:753-757
40. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR (1992) Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 89:46-52
41. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD (1990) IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 144:4226-4230
42. Manolagas SC (1998) The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci 840:194-204
43. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC (1998) Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13:793-802
44. Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116:1186-1194
45. Stein B, Yang MX (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15:4971-4979
46. Baumhauer J, O'Keefe R, Schon L, Pinzur M (2006) Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study. Foot Ankle Int 27:797-800
47. Sezer O (2005) Myeloma bone disease. Hematology 10:19-24
48. Iwamoto J, Takeda T, Ichimura S (2002) Increased bone resorption with decreased activity and increased recruitment of osteoblasts in osteogenesis imperfecta type I. J Bone Miner Metab 20:174-179
49. Tanaka Y, Nakayamada S, Okada Y (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflam Allergy 4:325
50. Evans BAJ, Elford C, Pexa A, Francis K, Hughes AC, Deussen A, Ham J (2006) Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res 21:228-236
51. Wang X, Seed B (2003) A PCR primer bank for quantitative gene expression analysis. Nucl Acids Res 31:e154
52. 3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 46:2023-2034
53. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354
54. Bost KL, Ramp WK, Nicholson NC, Bento JL, Marriott I, Hudson MC (1999) Staphylococcus aureus infection of mouse or human osteoblasts induces high levels of interleukin-6 and interleukin-12 production. J Infect Dis 180:1912-1920
55. 3 adenosine receptor. J Biol Chem 270:16895-16902
56. 1 receptor in DDT1MF-2 cells. Eur J Pharmacol 413:151
57. Peck W, Carpenter J, Shuster R (1976) Adenosine-mediated stimulation of bone cell adenylate cyclase activity. Endocrinology 99:901-909
58. Takahashi N, Tetsuka T, Uranishi H, Okamoto T (2002) Inhibition of the NF-kB transcriptional activity by protein kinase A. Eur J Biochem 269:4559-4565
59. 2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell Immunol 223:120-132
60. Song Z, Chen T, Deaciuc IV, Uriarte S, Hill D, Barve S, McClain CJ (2004) Modulation of endotoxin stimulated interleukin-6 production in monocytes and Kupffer cells by S-adenosylmethionine (SAMe). Cytokine 28:214-223
61. Phelps PT, Anthes JC, Correll CC (2006) Characterization of adenosine receptors in the human bladder carcinoma T24 cell line. Eur J Pharmacol 536:28-37
62. 2a adenosine receptors. J Biol Chem 272:337-344
63. 2b receptor from human brain. Biochem Biophys Res Commun 187:86
64. 2b receptor recruits divergent pathways to regulate ERK1/2 and p38. Exp Cell Res 290:168-176
65. Eliasson L, Ma X, Renstrom E, Barg S, Berggren P-O, Galvanovskis J, Gromada J, Jing X, Lundquist I, Salehi A, Sewing S, Rorsman P (2003) SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 121:181-197
66. 2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2.piccolo complex in cAMP-dependent exocytosis. J Biol Chem 277:50497-50502
67. 2+ release and exocytosis in pancreatic beta-cells. J Biol Chem 278:8279-8285
68. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, Seino S (2001) Critical role of cAMP-GEFII.Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046-46053
69. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S (2000) cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2:805-811
70. Kaneko M, Takahashi T (2004) Presynaptic mechanism underlying cAMP-dependent synaptic potentiation. J Neurosci 24:5202-5208
71. Sakaba T, Neher E (2003) Direct modulation of synaptic vesicle priming by GABAB receptor activation at a glutamatergic synapse. Nature 424:775-778
72. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR (2006) The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 177:1956-1966
73. 3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 316:71-78
74. 2a receptor agonists and endotoxin. Am J Pathol 160:2231-2244
75. 2a receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol Biol Cell 18:14-23
76. 3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 32:469-476
77. 3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 7:85-90
78. 2a receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (becaplermin gel). Inflammation 26:19-24